Page last updated: 2024-12-05

bromoacetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6227
CHEMBL ID60851
SCHEMBL ID23032
MeSH IDM0066179
PubMed CID6226
CHEBI ID192408
MeSH IDM0066179

Synonyms (100)

Synonym
2-bromo-acetic acid
inchi=1/c2h3bro2/c3-1-2(4)5/h1h2,(h,4,5
NCGC00091467-01
einecs 201-175-8
monobromessigsaeure [german]
epa pesticide chemical code 008702
un1938
acide bromacetique [french]
ccris 7886
brn 0506167
nsc 141
caswell no. 112a
kyselina bromoctova [czech]
2-bromoacetic acid
ai3-15301
nsc141
bromoacetate ion
acetic acid, bromo-
bromoethanoic acid
bromoacetic acid
.alpha.-bromoacetic acid
acide bromacetique
79-08-3
wln: qv1e
to ntu
monobromoacetic acid
nsc-141
bromoacetic acid, solid
DB02198
2-bromoacetyl group
bromoacetic acid, reagentplus(r), >=99%
bromoacetic acid, reagent grade, 97%
B0531
AKOS000118919
bdbm50119693
CHEMBL60851 ,
bromo-acetic acid
alpha-bromoacetic acid
2-bromanylethanoic acid
A839576
NCGC00091467-02
bxa ,
LMFA01090074
2-bromoethanoic acid
dtxsid7021495 ,
tox21_200657
dtxcid601495
cas-79-08-3
NCGC00258211-01
un 1938
unii-2b3hs32431
ec 201-175-8
2b3hs32431 ,
4-02-00-00526 (beilstein handbook reference)
bromoacetic acid, solid [un1938] [corrosive]
hsdb 7627
acetic acid, 2-bromo-
kyselina bromoctova
monobromessigsaeure
BP-20544
FT-0648951
bromoacetic acid-13c2
SCHEMBL23032
bromoacetic acid, 2-
bromoacetic acid [mi]
bromoacetic acid [hsdb]
carboxymethyl bromide
bromo acetic acid
monobromacetic acid
bromacetic acid
2-bromo acetic acid
bromoacetic-13c2acid
.alpha.-bromoethanoic acid
ch2brcooh
mfcd00002678
STL481895
J-519938
F2191-0223
bromoacetic acid, analytical standard
bromoacetic acid, purum, >=98.0% (t)
bromoacetic acid, reagentplus(r), >=99.0%
bromoacetic acid 1000 microg/ml in methyl-tert-butyl ether
FT-0772262
FT-0770735
Q421323
FT-0700929
STR00860
EN300-19170
44 - haloacetic acids
Z104473018
acetic acid, bromo-, ion(1-)
bromoacetate ,
bromoacetate(1-)
68-10-0
monobromoacetate
CHEBI:192408
2-bromoacetate
alpha-bromoacetate
KDPAWGWELVVRCH-UHFFFAOYSA-M
DTXSID60218189

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" We propose a model of toxic action based on monoHAA-mediated inhibition of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a target cytosolic enzyme."( Pyruvate remediation of cell stress and genotoxicity induced by haloacetic acid drinking water disinfection by-products.
Dad, A; Jeong, CH; Pals, JA; Plewa, MJ; Wagner, ED, 2013
)
0.39
"Chronic exposure to drinking water disinfection byproducts has been linked to adverse health risks."( Human cell toxicogenomic analysis linking reactive oxygen species to the toxicity of monohaloacetic acid drinking water disinfection byproducts.
Attene-Ramos, MS; Pals, J; Plewa, MJ; Wagner, ED; Xia, M, 2013
)
0.39
" Therefore, the DNA damage-responsive p53 pathway may be an important piece of information to fill in a gap in the adverse outcome pathway framework for the assessment of HBQs."( In Vitro Cytotoxicity and Adaptive Stress Responses to Selected Haloacetic Acid and Halobenzoquinone Water Disinfection Byproducts.
Escher, BI; Leusch, FD; Plewa, MJ; Procházka, E, 2015
)
0.42
" However, during disinfection, toxic disinfection byproducts (DBPs) are formed."( Energy of the Lowest Unoccupied Molecular Orbital, Thiol Reactivity, and Toxicity of Three Monobrominated Water Disinfection Byproducts.
Pals, JA; Plewa, MJ; Wagner, ED, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" Exposure to HAAs is influenced by consumption patterns and diet of individuals thus their bioavailability is an important parameter to the overall toxicity."( In vitro bioacessibility and transport across Caco-2 monolayers of haloacetic acids in drinking water.
Faria, MA; Ferreira, IMPLVO; Mansilha, C; Melo, A; Pinto, E, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" In rats dosed with DBAA, serum testosterone fell to 17% of control 2 days after a single dose of 1250 mg/kg but returned to control levels by Day 14."( Acute spermatogenic effects of bromoacetic acids.
Dyer, CJ; Klinefelter, GR; Linder, RE; Strader, LF; Suarez, JD, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organohalogen compoundA compound containing at least one carbon-halogen bond (where X is a halogen atom).
carboxylic acidA carbon oxoacid acid carrying at least one -C(=O)OH group and having the structure RC(=O)OH, where R is any any monovalent functional group. Carboxylic acids are the most common type of organic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
UDP-N-acetylmuramoyl-pentapeptide biosynthesis I (meso-diaminopimelate containing)1738
anhydromuropeptides recycling I1348
peptidoglycan biosynthesis I (meso-diaminopimelate containing)1142
nicotinate degradation I833

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency4.65890.006038.004119,952.5996AID1159521
thyroid stimulating hormone receptorHomo sapiens (human)Potency5.01190.001318.074339.8107AID926; AID938
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.00070.000214.376460.0339AID588532
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.18710.000229.305416,493.5996AID743075
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency74.97800.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)Ki77,000.00000.19004.83279.6000AID165176
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID384212Mutagenic activity in Salmonella Typhimurium TA100 assessed as logarithm of his+ revertant number increasing activity by amens test2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Halogenated derivatives QSAR model using spectral moments to predict haloacetic acids (HAA) mutagenicity.
AID33871The compound was tested for the ability to inactivate mouse liver alcohol dehydrogenase in the absence of NAD+K1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Inactivation of liver alcohol dehydrogenases and inhibition of ethanol metabolism by ambivalent active-site-directed reagents.
AID23443Partition coefficient (logP)1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.
AID33878The compound was tested for the ability to inactivate rat liver alcohol dehydrogenase in the absence of NAD+K1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Inactivation of liver alcohol dehydrogenases and inhibition of ethanol metabolism by ambivalent active-site-directed reagents.
AID165176Dissociation constant towards Protein-tyrosine phosphatase 1B receptor-inhibitor complex was determined using PNP as substrate2002Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21
alpha-bromoacetophenone derivatives as neutral protein tyrosine phosphatase inhibitors: structure-Activity relationship.
AID33879The compound was tested for the ability to inactivate rat liver alcohol dehydrogenase in the presence of 1 mM NAD+K1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Inactivation of liver alcohol dehydrogenases and inhibition of ethanol metabolism by ambivalent active-site-directed reagents.
AID165175First-order rate constant (K inact) for conversion of the ExI complex (Protein-tyrosine phosphatase 1B -inhibitor complex) into the covalent adduct, EI was determined using PNP as substrate2002Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21
alpha-bromoacetophenone derivatives as neutral protein tyrosine phosphatase inhibitors: structure-Activity relationship.
AID227010Ratio between dissociation constant and First-order rate constant (Ki / K inact) was determined2002Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21
alpha-bromoacetophenone derivatives as neutral protein tyrosine phosphatase inhibitors: structure-Activity relationship.
AID448096Dissociation constant, pKa of the compound2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Characterization of alpha-nitromethyl ketone as a new zinc-binding group based on structural analysis of its complex with carboxypeptidase A.
AID33873The compound was tested for the ability to inactivate mouse liver alcohol dehydrogenase in the presence of 1 mM NAD+K; Slow inactivation1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Inactivation of liver alcohol dehydrogenases and inhibition of ethanol metabolism by ambivalent active-site-directed reagents.
AID33719The compound was tested for the ability to inactivate horse liver alcohol dehydrogenase in the presence of 1 mM NAD+k1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Inactivation of liver alcohol dehydrogenases and inhibition of ethanol metabolism by ambivalent active-site-directed reagents.
AID33866The compound was tested for the ability to inactivate human liver alcohol dehydrogenase in the absence of NAD+K1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Inactivation of liver alcohol dehydrogenases and inhibition of ethanol metabolism by ambivalent active-site-directed reagents.
AID33714The compound was tested for the ability to inactivate horse liver alcohol dehydrogenase in the absence of NAD+k1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Inactivation of liver alcohol dehydrogenases and inhibition of ethanol metabolism by ambivalent active-site-directed reagents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (123)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (28.46)18.7374
1990's22 (17.89)18.2507
2000's23 (18.70)29.6817
2010's33 (26.83)24.3611
2020's10 (8.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.68 (24.57)
Research Supply Index4.81 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index87.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews2 (1.64%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other120 (98.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]